Isuzinaxib (APX-115 free base, Ewha-18278 free base) is a potent, orally active inhibitor of pan NADPH oxidase (pan-Nox) with Ki of 1.08 μM, 0.57 μM, and 0.63 μM for Nox1, Nox2 and Nox4, respectively. APX-115 free base (Ewha-18278 free base) significantly suppresses the expression of inflammatory molecules including MCP-1/CCL2, IL-6, and TNFα in the diabetic kidney.
[1] Jung Hee Joo, et al. Sci Rep. 2016 Mar 15;6:22389. [2] Jin Joo Cha, et al. Lab Invest. 2017 Apr;97(4):419-431.
















